Friday, January 30, 2015 9:52:19 AM
I don't trade on nor pay for the info, but my sources have been extremely accurate.
Unfortunately they simply repeat what management has been saying and that, as you say, can be quite worthless. Some may even call it being fleeced.
By the way, receiving inside information is perfectly legal as long as you don't trade on it. Bloomberg, CNBC, etc. do so all the time citing "anonymous sources." I have never traded a single share of NNVC. I simply enjoy the story.
I mean, how could one not? For example, you have a CEO claiming a Tox study that tears apart the insides of animals won't harm animals. You can't pay for this level of humor.
Unfortunately they simply repeat what management has been saying and that, as you say, can be quite worthless. Some may even call it being fleeced.
By the way, receiving inside information is perfectly legal as long as you don't trade on it. Bloomberg, CNBC, etc. do so all the time citing "anonymous sources." I have never traded a single share of NNVC. I simply enjoy the story.
I mean, how could one not? For example, you have a CEO claiming a Tox study that tears apart the insides of animals won't harm animals. You can't pay for this level of humor.
The SwingTrade Portfolio is up 5.8% YTD through 01/27/15, 36.2% in 2014, 83.5% in 2013, and 546.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110307454
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
